In the Claims

Please cancel claims 1-11 without prejudice to applicants' right to pursue the subject matter of these claims in this or a subsequent application.

Please add new claims 12-25 pursuant to 37 C.F.R. §1.121 as modified by 68 Fed. Reg. 38611 (June 30, 2003) as follows:

1. - 11. (Canceled)

12. (New): N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.

13. (New): A hydrate form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate of claim 12.

14. (New): A monohydrate form of the N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate of claim 12.

15. (New): A pharmaceutical composition which comprises the compound of claim 12 and a pharmaceutically acceptable carrier.

16. (New): The pharmaceutical composition of claim 15, comprising from about 0.001 mg to about 100 mg of the compound.

17. (New): The pharmaceutical composition of claim 16, comprising from about 1 mg to about 35 mg of the compound.

18.(New): The pharmaceutical composition of claim 16, comprising from about 0.05 mg to about 7 g of the compound.

19.(New): The pharmaceutical composition of claim 17, comprising from about 0.2 g to about 2.5 g of the compound.

20.(New): The pharmaceutical composition of claim 19, in the form of a tablet, capsule, pill, powder, sustained release formulations, solution, parenteral injection as a sterile solution, suspension or emulsion, or suppository.

21.(New): The pharmaceutical composition of claim 20, in the form of a parenteral injection.

22.(New): The pharmaceutical composition of claim 20, in the form of a tablet.

23.(New): A method of treating a mammal suffering from a hyperproliferative disorder which comprises administering to said mammal an amount of the compound of claim 12 therapeutically effective to inhibit the epidermal growth factor receptor ("EGFR") in the mammal, so as to thereby treat the mammal.

24.(New): The method of claim 23 wherein the hyperproliferative disorder is a cancer selected from the group consisting of brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, oesophageal, gynecological and thyroid cancer.

25.(New): The method of claim 23 further comprising administering to said mammal a therapeutically effective amount of a compound selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell-cycle inhibitor, enzymes, topoisomerase, inhibitors, biological response modifiers, anti-hormones, and anti-androgens.